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ABSTRACT 
BRCA testing received much publicity following Angelina Jolie’s editorial ‘My Medical 
Choice’ in May 2013 and updated NICE clinical guidance (CG164) in June 2013.  We assessed 
the effect of these two concurrent events on BRCA testing in one UK catchment area and relate 
this to socioeconomic deprivation. A database of 1393 patients who received BRCA testing was 
collated. This included individuals with breast/ovarian cancer, and those unaffected by cancer, 
where a relative has a ≥10% probability of carrying a BRCA variant which affects function. A 
segmented regression was conducted to estimate changes in testing. To examine the relative 
distribution of testing by deprivation, the deprivation status of patients who received testing 
was examined.  
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Between April 2010-March 2017, testing increased 11-fold and there was an 84% increase 
(P=0.006) in BRCA1/2 testing in the month following both publications.  In the pre-publication 
period,  there was no statistically significant difference in testing between advantaged and 
disadvantaged areas (OR 1.21 95% CI 0.99-1.48; P=0.06). In the post-publication period 
helped by a larger sample size, the difference was statistically significant (OR 1.18 95% CI 
1.08-1.29; P=0.0002) and of a similar magnitude to the pre-publication period. Testing 
increased following Jolie’s editorial and NICE guidance update. However further research is 
needed to examine differences in testing by deprivation group which adjusts for confounders. 
    
Key Words: Hereditary Breast Ovarian cancer; Equity; Uptake  
INTRODUCTION 
Breast cancer (BC) is the most commonly diagnosed cancer in women in the United Kingdom 
(UK) with an approximate lifetime risk of 12-13%1,2.  Ovarian cancer (OC) has a lifetime risk 
of 1.4-2.5%.1,3 Breast cancer affects men with a much lower lifetime risk of <1%.4 Although 
the susceptibility factors are unclear in the majority of patients with breast and ovarian cancer, 
some of these cancers are caused by germline variants which affect function in BRCA1 or 
BRCA2, with variation in the relative contribution of BRCA1 and BRCA2.  
It has been estimated that germline variants in BRCA which affect function exist in 0.2-0.3% 
of the overall general population, in 5-10% of patients with BC,5 in 5-13% of patients with 
OC,3 and in 0.4-1.2% of patients with prostate cancer (PC).6  BRCA germline variants have 
also been found to be associated with cancers of the pancreas, stomach, skin, colon and others.7 
Identification of patients with BRCA variants is important as the presence of such germline 
variants affects treatment, follow-up and cancer prevention.8 Further, risk-reducing lifestyle 
modifications, medications and procedures may be indicated, for example, bilateral 
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mastectomy and/or salpingo-oophorectomy.9,10 Studies have found BRCA testing to be 
clinically effective and cost-effective, particularly in individuals with a family history of 
hereditary breast and breast and ovarian cancer (HBOC).  Indeed, a recent modelling study 
found that implementation of BRCA testing across the general female population aged 30 years 
and older would be cost-effective.11  
On 14 May 2013, the celebrity Angelina Jolie raised public awareness of BRCA testing globally 
following her widely publicized New York Times editorial ‘My Medical Choice.’12 The 
editorial described Jolie’s experience, why she decided to undergo BRCA testing and why she 
opted to undergo risk-reducing procedures (a preventative double mastectomy) because of her 
BRCA status.13–15 About the same time, on 25 June 2013, the National Institute for Health and 
Care Excellence (NICE) published its updated guidance for Familial Breast Cancer Testing 
[CG164].16 NICE recommended that testing should be conducted in patients with ovarian or 
breast cancer, or in their relatives, where the probability of combined BRCA1 or BRCA2 
variants which affect function is ≥10%.16 At the same time, there was considerable publicity 
about the potential use of chemoprevention using tamoxifen or raloxifene.14  
The extent to which Jolie’s editorial and NICE CG164 led to changes in uptake rates of BRCA 
testing in terms of equity of access has not been previously explored in the UK.16  Disparities 
in cancer survival by deprivation groups persist for most types of cancer and also across 
geographical settings.17–19 The NHS atlas of variation (2013) reported that North West England 
has one of the lowest rates of BRCA genetic testing.20 However, in 2016/17, the lowest rate 
reported by UK Genetic Test Network (UKGTN) was in Yorkshire and Humber 
Commissioning Region (23.4 per 100,000) and the highest was in the South East 
Commissioning Hub (71.1 per 100,00).21  To explore disparities within the North West region, 
the aim of this study was to analyse trends in uptake rates following Jolie’s editorial and NICE 
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CG164 and relate this to equity of access to BRCA testing. This study followed Standards for 
Reporting Implementation Studies (STaRI) guidelines for transparent and accurate reporting 
of implementation studies.22   
METHODS 
Study population and data sources  
Research was conducted using retrospective, routinely collected hospital data from the 
Merseyside and Cheshire Regional Genetic Service (RGS) hosted by Liverpool Women’s NHS 
Foundation Trust. The RGS is responsible for care in Merseyside and Cheshire (with the 
exception of boundary areas) serving a catchment area of approximately 2.4 million people. 
We identified women aged ≥18 years old from April 2010 and March 2017 who received BRCA 
testing.  
For the purposes of this research, BRCA testing refers to DNA sequencing analysis of both 
BRCA1 and BRCA2 genes and comparing that analysis to reference sequence. Testing also 
included multiplex ligation-dependent probe amplification (MLPA) dosage analysis to exclude 
the presence of whole deletion or duplication. The method of sequence analysis has changed 
over the timeframe of the study from bi-directional fluorescent sequencing in 2010 to long 
range polymerase chain reaction (PCR) and next generation sequencing on Illumina MiSeq 
(minimum 100x coverage) using an in-house variant calling bioinformatic pipeline with sanger 
confirmation of variants called or areas of the gene with less than 100x coverage.  
The NICE guideline for CG164 updated previous guidance on familial breast cancer, published 
in 2004 and 2006.23,24 BRCA testing was expanded to individuals affected with a relevant 
cancer (except those with Ashkenazi Jewish ancestry) if the probability of combined BRCA1 
and BRCA2 variants which affect function was 10% or more (CG164 1.5.13). In addition, 
 
Page 6 of 21 
 
BRCA testing expanded to individuals unaffected by cancer if their combined BRCA1 and 
BRCA2 functional variant probability was ≥10% and an affected relative was unavailable for 
testing (CG164, 1.5.12).25 Specifically, this paper does not include predictive BRCA gene 
testing which describes the use of a BRCA test in an asymptomatic person to predict future risk 
of disease where a variant within a BRCA gene is already known within the family and the 
patient’s DNA is tested for that variant alone (CG164, 1.3.6).16,26  This will be the subject of a 
separate paper. 
Baseline characteristics of patients who received BRCA testing and also the study setting 
population were collected. Patients aged <18 years old were excluded from the dataset as per 
ethics requirements. In addition, 5.7% (80/1393) of patients were registered at an address 
outside of England and were therefore excluded from the dataset as information on their 
respective Index of Multiple Deprivation (IMD) based on their Lower Layer Super Output Area 
(LSOA) was not available.  
Socioeconomic deprivation is intrinsically linked to health, and it is widely acknowledged that 
with many diseases, the incidence is higher in more deprived populations.27 These inequalities 
are due to complex structural factors including differential exposure to risk factors like stress 
and pollution, protective factors like education and good housing, and lifestyle risk factors like 
smoking, alcohol and unhealthy diet.28 Supplementary Figure 1(a) illustrates the pattern of 
deprivation within each area, taken from the Index of Multiple Deprivation for 2015 and  
(b) illustrates the incidence of new cases for all cancers for 2011-2015 within Merseyside and 
Cheshire. The population is diverse in terms of social deprivation, including some of the most 
deprived and least deprived areas in England. 
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Time periods of interest 
Our defined time point of interest was the combination of the New York Times editorial by 
Angelina Jolie on 14 May 2013 and the release of NICE CG164 guidance on 25 June 2013.12,16 
These combined publications provided information and guidance on the use of BRCA testing 
for the diagnosis and treatment specifically for breast and ovarian cancers and risk assessment 
of family members. In this study we compare ‘pre-publication’ with ‘post-publication’ as both 
the Jolie editorial and the NICE guidance were published within weeks of each other in 2013. 
Consequently, their effects could not be separated. 
Measures 
We summarize baseline characteristics of patients who received BRCA testing which included 
gender, age, type of cancer, variant status and IMD. Monthly trends in the proportion of patients 
who received testing were measured over time. Subsequently, we analyzed equity of access to 
BRCA testing by deprivation group, classified by the IMD pre and post-publication.  
Based on postcode of residence, each patient who received BRCA testing was assigned to a 
LSOA and this was mapped to an IMD quintile calculated across the whole of England using 
this measure. LSOAs are the smallest geographical units for which IMD scores are available. 
From the 2011 Census, there were 32844 LSOAs used in the 2015 Indices of Deprivation in 
England.29 Each LSOA contains a small cluster of postcodes with comparable characteristics 
and have a mean population of approximately 1500 people. LSOAs are not necessarily 
homogenous in terms of sociodemographics, although often border natural geographical 
features like roads and rail lines.29  
For all the recipients of BRCA testing at Merseyside and Cheshire RGS, their LSOA were 
mapped to an IMD quintile from the 2015 Indices of Deprivation in England.29 The comparator 
group, described as ‘the catchment population’ included all LSOAs which were located within 
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local authority (LA) districts in Merseyside and Cheshire. As such, the LSOA Mid-Year 
Population Estimates for Mid-2016 from within the LA districts (including Cheshire East, 
Cheshire West and Chester, Halton, Knowsley, Liverpool, Sefton, St. Helens, Warrington and 
Wirral) were mapped to IMD quintiles and the population for each IMD quintile was calculated 
for the catchment population.30  
The IMD score combines seven indicators (income, employment, health deprivation and 
disability, education, skills and training, barriers to housing and services, crime, and living 
environment), into a single deprivation index. We defined equity of access based on the 
philosophy of the NHS in the UK as having an objective of providing equal health care access 
for equal health care need.31 
Statistical analysis 
The crude rate of BRCA testing was presented as it was assumed that individual-level variables 
remained relatively stable over the study period.32 The data was adjusted to assess monthly 
trends in testing from April 2010 to March 2017 per 100,000 population for the catchment area 
of Merseyside and Cheshire RGS. Analyses were based on 37 monthly pre-publication data 
points (Apr 2010–Apr 2013) and 45 monthly post-publication data points (July 2013–Mar 
2017). An interrupted time series (ITS) analysis was performed to estimate the overall 
publication impact (intervention effect) by predicting what would have been observed post-
publication (or counterfactual rates) had pre-publication levels and/or trends continued 
uninterrupted and comparing this with what was modelled using observed post-publication 
data. The endpoint of the observed post-publication period (March 2017) was used to calculate 
the average difference over the post-publication time points on the aggregated time-series to 
estimate two parameters of interest associated with both publications: change in subsequent 
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level of testing and change in subsequent trend prior to the publications, the level of change in 
testing following the publications and following through the remainder of the study period.33,34  
ITS, known as segmented regression analysis, is a strong quasi-experimental alternative when 
randomized design is not feasible and has the causal hypothesis that observations after 
treatment have a different level (or slope) from those before the intervention (or in this case the 
intervention is the two publications). The regression model was specified as following: Ŷt = β0 
+ β1 * timet + β2 * interventiont + β3 * post_interventiont + et. Here Ŷt  is the incidence of 
BRCA testing at time point t. β0  estimates the baseline level of the outcome just before the 
beginning of the time series. β1 estimates the pre-intervention trend, β2 the change in the level 
between the time point immediately before vs. after the lag period and β3 the change in trend 
occurring immediately after the lag period. The final model specification was derived using a 
backward-stepwise approach (P<0.1) to remove non-significant regression terms in order to 
maximize statistical power. A generalized least squares (GLS) model with autoregressive 
moving average (ARMA 6,0) process was fitted and Durbin-Watson statistics indicated no 
significant autocorrelation. Finally, the likelihood ratio test and residual plot indicated that the 
model was correctly specified. The absolute and relative effect of the publications was 
calculated and the 95% confidence intervals (CI) for coefficients were calculated by the 
bootstrapping method. Statistical and economic analysis was conducted using R (version 3.42) 
and RStudio 1.1.383.35    
To address the secondary aim of this study, the IMD score for each member of the catchment 
population was defined as that of their respective LSOA for the purposes of analysis. 
Deprivation scores were divided into national quintiles for the catchment population. Odds 
ratios and associated confidence intervals were calculated for the quintiles in a binary logistic 
regression analysis.   
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RESULTS  
Between April 2010 and March 2017, 1394 BRCA tests were undertaken, of whom 170 (12.2%) 
were identified with a BRCA variant which is known to affect function. Patient baseline 
characteristics are described in Table 1. Female patients comprised 96.2% of the study 
population and the mean age at the time of the BRCA test was 53.4 years (SD 13.0; range 16-
93 years). Of the total study population, 58.5% had breast cancer, 23.2% had ovarian cancer, 
2.4% had BOC, 3.0% had another type of cancer and 12.8% were personally unaffected by 
cancer but their probability of carrying BRCA variants which affect function was 10% or more 
and an affected relative was unavailable for testing. The likelihood that patients were identified 
with a known functional variant was significantly lower by 36% in the post-publication period 
(11.1%; 129/1157) compared with the pre-publication period (17.4%; 41/236; P=0.008).  
At the beginning of the period of observation, there were an estimated 0.14 BRCA tests received 
per 100,000 population per month and a per month increase of 0.01 BRCA tests received per 
100,000 population (P=0.085) over the period March 2010 and April 2013 (Table 2). Based on 
our segmented regression analysis, testing increased by 0.30 per 100,000 (95% CI 0.09-0.51) 
following the combined publications, which was approximately an 84.3% increase (P=0.006), 
followed by a 0.01 per 100,000 population (95% CI 0.01-0.02) (P=0.002) increased trend in 
testing per month.  
At the end of the post-publication observation period (45 months follow-up), it was estimated 
that testing had increased from 0.62 to 1.52 per 100,000 population. This translated to an 
approximate 145% (95% CI 30.4-295.7%) increase in testing, or an absolute increase in testing 
of 0.89 per 100,000 population (95% CI 0.04-1.13). Therefore, between April 2010 and March 
2017, testing rates increased approximately 11-fold from 0.14 to 1.52 tests per 100,000 
population per month. The trend in incidence of BRCA testing is illustrated in Figure 2.  
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Supplementary Figure 2 illustrates the standardised change in uptake of BRCA testing pre and 
post-publication by IMD quintile (1=most deprived to 5=least deprived). While pre-publication 
testing was limited, the number of BRCA tests increased more than four-fold per year across 
all quintiles post-publication. However, there were large disparities in uptake across the 
different geographical areas (Figure 2).  
Social deprivation data was collected for all LSOAs within the catchment area of Merseyside 
and Cheshire. The catchment area deprivation scores were divided into population-matched 
quintiles, with proportions of BRCA tests received calculated for each. A chi-squared test 
assessed whether the observed frequencies of BRCA testing by IMD quintiles matched the 
expected frequencies. We found that BRCA testing by IMD quintile differed significantly from 
the expected proportion of BRCA testing given the catchment population distribution (P=0.04), 
shown in Figure 3.   
In Table 3, odds ratios were calculated for each quintile relative to the incidence within the 
most deprived group (first quintile). In the pre-publication period, there was no statistically 
significant difference in testing between the advantaged and disadvantaged areas (OR 1.21 
95% CI 0.99-1.48, P=0.06).  During the post-publication period, testing was significantly 
higher as deprivation reduced (OR 1.18 95% CI 1.08-1.29, P<0.001), but this was helped by 
the higher sample size in the post-publication period. 
An assessment of testing by quintile found that pre-publication, the odds of receiving BRCA 
testing were higher in the fourth quintile compared to the first (OR 1.45 95% CI 1.00-2.11, 
P<0.05). Post-publication, the odds of receiving testing were higher in the third and fourth 
quintile, compared to the first quintile (OR 1.24 95% CI 1.04-1.48, P<0.05) and (OR 1.48 95% 
CI 1.09-1.54, P<0.05). However, as part of sensitivity analysis, we found that pre-publication, 
a significant increase in odds of BRCA testing were not found when comparing the fifth quintile 
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to the two most deprived quintiles (first and second combined). Likewise, post-publication, the 
odds of testing in the least deprived quintile compared to the two most deprived quintiles were 
not found to differ significantly.  
DISCUSSION  
This study found that the implementation of NICE clinical guidelines in combination with 
celebrity endorsement yielded an estimated 145% increase in BRCA testing. While NICE 
clinical guidelines are recommendations ‘as an option’, delayed implementation at a local level 
may have limited patient access for some.  
Whilst it was anticipated that both the publication of NICE CG164 and Jolie’s editorial were 
the main contributors to increased BRCA testing, it is of course possible that there were other 
contributors. As advancements in genomic technologies continue and become more 
widespread, a ‘mainstreaming model’ has been introduced where BRCA testing is now offered 
as part of routine gynae-oncology care pathway and such streamlining may have also 
contributed to increased testing.36 This mainstreaming model involved up-skilling oncology 
specialists (through online, face-to-face learning packages and written algorithms) to consent, 
order, interpret and deliver results for genetic testing.37,38    
Increased testing may also be the result of advances in effective treatment options that are 
tailored to BRCA variants, such as olaparib, a poly ADP-ribose polymerase (PARP) inhibitor 
which has been proven to prolong progression-free survival in BRCA positive breast and 
ovarian cancers.39,40 In essence, increased treatment options may have encouraged clinicians to 
offer testing due to an improved risk-benefit profile. Further, as direct-to-consumer (DTC) 
BRCA tests have become widely available, it is possible that marketing campaigns and 
confirmatory testing due to the use of DTC tests may have increased demand.  
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Whilst it was anticipated that both the publication of CG164 and Jolie’s editorial were the main 
contributors to increased BRCA testing, the extent to which these contributors may have 
impacted testing in different socioeconomic groups based on their differential awareness and 
demand is uncertain. Clearly, there are also confounding factors, such as differences in cancer 
incidence in different socioeconomic groups, which also need to be considered. A recent 
qualitative study by Wright et al. (2018) found that some patients felt regretful and angry when 
BRCA testing was offered to them as many had already been diagnosed with cancer and that 
the timing of the test was illogical. While some patients had heard of BRCA testing, they 
believed that they were ineligible based on beliefs shaped by recent media discussions as no 
members of their family had breast cancer.41  
The identification of BRCA variants in ovarian cancer patients may have significant financial 
implications as olaparib has a UK list price of £3950 per pack per month.42 As such, 
implementation studies are needed to examine care delivery to ensure access is based on actual 
health care need.  
An important study limitation was that the rate of BRCA testing was unadjusted. Therefore, the 
comparison between rates of BRCA testing pre- and post-publication of CG164 and Jolie’s 
editorial may have been confounded by changes in individual-level variables such as age, sex 
and other factors which impact the clinical need for BRCA testing. While this study found that 
socioeconomic deprivation may be associated with lower rates of BRCA testing, multiple 
factors may have contributed to this. However, multivariate analysis was not possible in this 
study due to a lack of comparative data available for the catchment population. The significance 
of the results of this study are nevertheless interesting and with clinical relevance as post-
publication the observed rate of BRCA testing was found to be higher in the least deprived 
population compared to the most deprived population.  
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Other studies in the USA have found that rates of referrals for BRCA testing in patients with a 
diagnosis of OC and BC differed by race and insurance status.43,44 In addition, a survey found 
that ethnic minority BC patients were less willing to undergo molecular testing.45 Another 
study for genetic testing for Long QT syndrome (LQTS) found that those who were anxious or 
depressed were more likely to perceive barriers to communicating genetic information to 
family members.46 Meanwhile, a preference elicitation study found that the valuation of genetic 
testing for colorectal cancer also varied by income and employment status of the patient.47  
In cystic fibrosis (CF), implementation of CF newborn screening programs across the US 
remains suboptimal in nonwhite populations due to poor characterization of CFTR gene 
variants in diverse ethnic groups.48 Similarly, high-risk APOL1 genotypes increase the risk of 
kidney disease by seven-fold, and they are more common in individuals of African descent. 
However, the mechanisms by which APOL1 genotypes increase the risk of kidney disease 
remains poorly understood, and thus treatments that specifically target individuals with high-
risk genotypes have been slow to develop.49 Therefore, potential disparities in genetic testing 
may not only depend on socioeconomic status, but also on differing clinician and patient 
preferences, poor characterization of genetic variants and insufficient mechanisms to manage 
vulnerable patient populations.20,43,44,49,50 Thus, as with BRCA testing, the prevalence of disease 
in different population groups is an important factor to consider when analyzing disparities. 
Consequently, novel approaches including the analyses of patient level data, preference 
elicitation studies and qualitative research are needed to understand more about health care 
implementation.   
There remains a paucity of evidence to inform how different modalities of implementation of 
BRCA testing could be used to target vulnerable populations within the UK. Although one 
survey found that following celebrity endorsement from Angelina Jolie, there was increased 
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awareness of health challenges, more purposeful communication efforts may better assist 
public understanding given the complexity of the information.51 A survey found that the 
increased presence of HBOC in the media since Jolie’s disclosure led to greater awareness from 
people from different social backgrounds.13 However another study found that increased 
awareness of testing is not always associated with improved understanding about the 
implications of testing.51  
An economic study in the USA found that while BRCA testing increased following publication 
of Jolie’s editorial, the proportion of patients which consumed additional health care resources 
declined.52 Our study found that there was reduced likelihood that patients were identified with 
a variant which affects function in the post-publication period. Therefore, these findings 
highlight the importance of ensuring potential surges in health seeking do not result in 
unnecessary resource use that may not benefit patients at low risk. Although, in our study it 
was not possible to examine whether BRCA testing was guideline concordant due to a lack of 
personal and family history of cancer data. 
While this research has identified interesting findings relating to the impact of Jolie’s editorial 
and NICE guidelines and also differences in BRCA testing, the overall findings are subject to 
some limitations. All models are imprecise, despite the fact that Autoregressive Integrated 
Moving Average (ARIMA) models inherently account for autocorrelation, non-stationarity, 
and seasonality. However, estimates of the overall effect on rates of BRCA testing involved 
extrapolation which is inevitably associated with uncertainty. Furthermore, the regression 
method chosen assumed a linear trend over time and although it assumed larger standard errors 
in the post-publication period. The main threat to validity in interrupted time series analyses 
relate to time-varying confounding, such as co-interventions, possible changes in treatment 
coding, or changes in the population under study.53 Another problem with such analyses is that 
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interventions may be implemented at different rates and inconsistently and therefore, there 
remains uncertainty in the overall impact of both publications. 
An additional study limitation was that in designing the analysis, it was not feasible to add a 
non-equivalent no-treatment control group. It is not obvious why there would be variation in 
the provision of health services as both the Merseyside and Cheshire Regional Genetic Service 
(RGS) are regional, cover the same geographical footprint and both work to standard testing 
protocols. However, we have only accessed data from one RGS, which is the sole provider for 
genetic testing within the region, and thus, any patient accessing testing through another 
provider is not included. Those patients living near the boundary of the region may have 
attended the adjacent RGS or some patients may have accessed private testing. Another 
limitation relates to the sensitivity of IMD quintiles matched to each LSOA. Moreover, within 
each LSOA there may be significant variation in terms of deprivation and this is an important 
consideration when interpreting the results. Additionally, recorded BRCA data might be subject 
to recording or adjudication errors, and the reliability of the coding of BRCA tests might have 
changed over time. However, there was no evidence of changes in treatment coding or 
significant changes in the underlying study population.  
CONCLUSIONS  
This study shows that clinical guidelines and celebrity endorsements may have had a significant 
impact on health service use in terms of the rate of BRCA testing. However, while such 
publications and publicity may increase awareness and uptake, the proportion of patients 
identified with having a BRCA variant which affects function decreased. This highlights the 
importance of ensuring that potential surges in health seeking do not translate to inappropriate 
resource use that may not benefit patients at low risk and that may result in a significant cost 
burden to the taxpayer. The NHS in the UK has the philosophy of offering ‘a comprehensive 
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service, available to all’ irrespective of ability to pay.31 As such, additional studies that control 
for confounders are needed to establish whether access to BRCA testing is based on actual 
health care need.  
Supplementary information is available at the European Journal of Human Genetics website. 
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TABLES 
Table 1 Baseline study population demographics 
 
Table 2 Temporal trends in receipt of BRCA testing from 2010 to 2017 (per 100,000 population) 
 
 
Table 3  Comparative odds ratios (95% CI) for each population-matched IMD quintile 
FIGURES 
Figure 1 Standardized incidence of BRCA testing per 100,000 population.  The red dots indicate the 
observed uptake per month. The red line represents the trend line pre and post-publication of Jolie’s 
editorial and NICE CG164. The blue dashed line represents the extrapolated pre-publication regression 
line. *Post-publication is the period which followed the New York Times Editorial ‘My Medical 
Choice’ by Angelina Jolie and update to NICE CG164    
 
Figure 2 Map of Merseyside and Cheshire illustrating receipt of BRCA testing: (a) Pre-
Publication and (b) Post-Publication 
 
Figure 3 Distribution of cancer BRCA testing Pre and Post-Publication 
 
